Comparing vTv Therapeutics (NASDAQ:VTVT) and Milestone Pharmaceuticals (NASDAQ:MIST)

vTv Therapeutics (NASDAQ:VTVT) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

vTv Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for vTv Therapeutics and Milestone Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1	1	6	1	2.78
Milestone Pharmaceuticals	1	1	4	1	2.71

vTv Therapeutics presently has a consensus target price of $55.83, indicating a potential upside of 79.07%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 736.60%. Given Milestone Pharmaceuticals’ higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than vTv Therapeutics.

Profitability

This table compares vTv Therapeutics and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Valuation and Earnings

This table compares vTv Therapeutics and Milestone Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02 million	120.44	-$26.97 million	($1.06)	-29.42
Milestone Pharmaceuticals	$1.55 million	61.45	-$63.06 million	($0.69)	-1.11

vTv Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

vTv Therapeutics beats Milestone Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About vTv Therapeutics

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.